Publications

June 2006 (Revised April 2007)
Case

BioScale

By: H. Kent Bowen and Bradley R. Staats

In 2004, Mark Lundstrom must decide on a funding method and strategic approach for BioScale, a biotechnology company that he founded. BioScale has developed a microchip-based bioanalytical platform that can be used to detect very small concentrations of cells, viruses,... View Details

Keywords: Entrepreneurship; Science-Based Business; Capital; Financing and Loans; Partners and Partnerships; Biotechnology Industry

July 2016
Case

Product Portfolio Management at Genentech

By: Kevin Schulman and Jamie Gresh

Genentech, long the darling of the biotechnology industry, was acquired by Swiss pharmaceutical company Roche in 2009. The combined company retains the name Genentech in the US, but must now move to achieve the promises made at the time of this merger—to build from... View Details

Keywords: Portfolio Management; Drug Development; Postmerger Integration; Marketing Strategy; Mergers and Acquisitions; Integration; Biotechnology Industry; Biotechnology Industry; United States

February 2000 (Revised October 2000)
Case

Kendle International Inc.

By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs

Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details

Keywords: Acquisition; Financing and Loans; Venture Capital; Stock Options; Banks and Banking; Debt Securities; International Finance; Financial Strategy; Management Skills; Private Ownership; Initial Public Offering; Biotechnology Industry; Biotechnology Industry

May 2007 (Revised September 2008)
Case

Biocon Limited

By: Krishna G. Palepu and Ananth Chepuri

Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new... View Details

Keywords: Globalized Firms and Management; Innovation and Management; Leading Change; Growth and Development Strategy; Risk Management; Organizational Change and Adaptation; Biotechnology Industry; India

April 1993 (Revised October 1995)
Case

ALZA and Bio-Electro Systems (A): Technological and Financial Innovation

By: Josh Lerner and Peter Tufano

To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details

Keywords: Risk and Uncertainty; Technological Innovation; Business Subsidiaries; Decision Choices and Conditions; Corporate Finance; Biotechnology Industry; Biotechnology Industry

December 1999 (Revised August 2001)
Case

Millennium Pharmaceuticals, Inc. (A)

By: Stefan H. Thomke and Ashok Nimgade

Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details

Keywords: Cost Management; Financing and Loans; Medical Specialties; Retention; Growth and Development Strategy; Time Management; Product Development; Problems and Challenges; Alliances; Technology; Biotechnology Industry; Biotechnology Industry; Cambridge

January 2020
Case

Celata Bioinnovations

By: John R. Wells and Benjamin Weinstock

In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details

May 2009 (Revised August 2013)
Case

The DiagnoFirst Opportunity

By: Robert C. Pozen and Rukmini Balu

John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a genetic test that identified a subset of prostate cancer patients with a high risk of clinical... View Details

Keywords: Genetic Engineering; Genetically Modified; Genomics; Venture Capital; Patents; Genetics; Decision Choices and Conditions; Laws and Statutes; Investment; Science-Based Business; Biotechnology Industry

2010
Working Paper

Venture Capital Investment in the Clean Energy Sector

By: Shikhar Ghosh and Ramana Nanda

We examine the extent to which venture capital is adequately positioned for the rapid commercialization of clean energy technologies in the United States. While there are several startups in clean energy that are well-suited to the traditional venture capital... View Details

Keywords: Business Startups; Energy Generation; Venture Capital; Investment; Governing Rules, Regulations, and Reforms; Technological Innovation; Competition; Energy Industry; Energy Industry; United States

Read Now

Paul Gompers, Professor of Business Administration at the Harvard Business School, specializes in research on financial issues related to start-up, high growth, and newly public companies. Professor Gompers has an appointment in both the View Details

Keywords: information technology industry; information technology industry; information technology industry; information technology industry; information technology industry; information technology industry; information technology industry; information technology industry

September 2023 (Revised December 2023)
Case

TetraScience: Noise and Signal

By: Thomas R. Eisenmann and Tom Quinn

In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from... View Details

Keywords: Entrepreneurship; Business Growth and Maturation; Business Organization; Restructuring; Forecasting and Prediction; Digital Platforms; Analytics and Data Science; AI and Machine Learning; Organizational Structure; Network Effects; Competitive Strategy; Biotechnology Industry; Biotechnology Industry; United States; Boston

Michael Porter is an economist, researcher, author, advisor, speaker and teacher. Throughout his career at Harvard Business School, he has brought economic theory and strategy concepts to bear on many of the most challenging problems facing corporations, economies... View Details

Keywords: biotechnology; biotechnology; biotechnology; biotechnology; biotechnology; biotechnology; biotechnology; biotechnology; biotechnology

02 Dec 2002
Research & Ideas

The Secret of How Microsoft Stays on Top

industry or the biotechnology industry? Both industries share similarities with software, in that firms codify their intellectual property into libraries that can be reused and... View Details

Keywords: by Sean Silverthorne

Research Summary

Overview

The research activity of Stefano Denicolai regards the management of innovation and technology. His recent works investigate if and how the investment in intangible assets (IA) - especially knowledge assets, such as patents or copyright - impacts on the firm... View Details

Keywords: Innovation Management; International Entrepreneurship; Intangible Assets; Open Innovation; Innovation and Management; Entrepreneurship; Competitive Strategy; Technology Industry; Technology Industry; Technology Industry; Technology Industry

September 2013 (Revised August 2014)
Case

Claritas Genomics

By: Robert F. Higgins and Matthew Preble

Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new... View Details

May 2006 (Revised June 2006)
Case

Codon Devices

By: Joseph B. Lassiter III and David Kiron

In December 2005, 40-year-old John Danner was about to make his first presentation to the board of directors of Codon Devices, a one-year-old biotechnology start-up based in Cambridge, Massachusetts. After a month as the company's CEO, Danner was prepared to lay out... View Details

Keywords: Strategic Planning; Venture Capital; Intellectual Property; Governing and Advisory Boards; Genetics; Competitive Advantage; Science-Based Business; Business Startups; Growth and Development Strategy; Biotechnology Industry; Cambridge

Find at Harvard

March 1996
Case

Erox Corporation: Leverage Marketing

Erox Corp. is a biotechnology start-up that creates products containing synthetic human pheromones. It was founded in 1989, went public in 1993, and brought in a turnaround team in 1994. Sales ramped from $110,000 in 1993 to over $1 million in 1994, with prospects for... View Details

Keywords: Marketing Communications; Entrepreneurship; Biotechnology Industry